Prestige BioPharma (XKRX:950210) Change In Receivables : ₩0 Mil (TTM As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Prestige BioPharma Change In Receivables?

Prestige BioPharma's change in receivables for the quarter that ended in Dec. 2024 was ₩0 Mil. It means Prestige BioPharma's Accounts Receivable stayed the same from Sep. 2024 to Dec. 2024 .

Prestige BioPharma's change in receivables for the fiscal year that ended in Jun. 2024 was ₩5,102 Mil. It means Prestige BioPharma's Accounts Receivable declined by ₩5,102 Mil from Jun. 2023 to Jun. 2024 .

Prestige BioPharma's Accounts Receivable for the quarter that ended in Dec. 2024 was ₩3,789 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Prestige BioPharma's Days Sales Outstanding for the three months ended in Dec. 2024 was 111.01.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Prestige BioPharma's liquidation value for the three months ended in Dec. 2024 was ₩-8,093 Mil.

Prestige BioPharma Change In Receivables Historical Data

The historical data trend for Prestige BioPharma's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prestige BioPharma Change In Receivables Chart

Prestige BioPharma Annual Data

Trend

Jun20

Jun21

Jun22

Jun23

Jun24

Change In Receivables

9,772.70

1,246.60

179.08

-5,950.00

5,101.59

Prestige BioPharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Prestige BioPharma Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩0 Mil.

Prestige BioPharma (XKRX:950210) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Prestige BioPharma's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	3789.257	/	3114.81	*	91
=	111.01

2. In Ben Graham's calculation of liquidation value, Prestige BioPharma's accounts receivable are only considered to be worth 75% of book value:

Prestige BioPharma's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	242875.218	-	263062.965	+	0.75 * 3789.257	+	0.5 * 18505.452
=	-8,093

Prestige BioPharma Change In Receivables Related Terms

Thank you for viewing the detailed overview of Prestige BioPharma's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Prestige BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prestige BioPharma Ltd (XKRX:950210) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

2 Science Park Drive No. 04-13/14, Ascent Tower B, Singapore Science Park, Singapore, SGP, 118222

Website

https://www.prestigebiopharma.com

Prestige BioPharma Ltd is a biopharmaceutical company. The company is focused on the development of biosimilars and new antibody therapeutics. It focuses on oncology and immune disorders, developing new and similar antibody drugs for solid tumor, pancreatic cancer, and arthritis.

Prestige BioPharma Headlines

No Headlines